In a report released yesterday, Francois Brisebois from Oppenheimer maintained a Buy rating on Durect (DRRX), with a price target of $7.00. The company’s shares closed last Monday at $1.77.
According to TipRanks.com, Brisebois is a 1-star analyst with an average return of -2.9% and a 32.1% success rate. Brisebois covers the Healthcare sector, focusing on stocks such as Avadel Pharmaceuticals, Flexion Therapeutics, and Kala Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Durect with a $6.17 average price target, which is a 242.8% upside from current levels. In a report issued on October 30, Chardan Capital also initiated coverage with a Buy rating on the stock with a $7.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $3.95 and a one-year low of $0.95. Currently, Durect has an average volume of 1.01M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
DURECT Corp. is a biopharmaceutical company, which engages in the research, development, and manufacturing of pharmaceutical products. The company products include alzet and lactel. Its pipeline includes DUR-928, which focuses on lipid homeostasis, inflammation, and cell survival; and POSIMIR, which is an analgesic product intended to deliver bupivacaine to provide pain relief after surgery. The company was founded by James E. Brown and Felix Theeuwes on February 6, 1998 and is headquartered in Cupertino, CA.
